Meeting Home | SBT Home

Poster Listing

Angiogenesis

1. A Canine Hemangiosarcoma Xenograft Angiogenesis Model
   Stuart Helfand, N. Akhtar, M.L. Padilla, EB Dickerson, H. Steinberg

2. Von Willebrand Factor Antigen may be a Surrogate Marker for Biological Effect on Endothelial Cells in Patients with Solid Tumors Treated with Anti-Angiogenesis Compounds
   Paul Masci, S. Radka, C. Pasco, R. Aitchison, V. Parker, N. Usman, E.C. Borden, D. Weng

3. Quantification of Angiogenesis by Functional Computed Tomography (fCT) in a Rat Model
   Sith Phongkitkarun, S. Kobayashi, Z. Kan, Ty Lee, C. Charnsangavej

4. Copper Chelation Inhibits Endothelial Proliferation in Vitro
   Mary Sproull, Tamalee Scott, Cynthia Menard, Martin Brechbiel, Kevin Campahusen

5. TEM Expression in Cultured Endothelial Cells
   Beverly A. Teicher, Jennifer Walter-Yohrling, Rebecca Bagley, Cecile Rouleau, Mariana Nacht, Wen Zhang, Srinivas Shankara, Katherine Klinger, Bruce Roberts

6. Highly Efficient Naked DNA Delivery of a Soluble Form of Vascular Endothelial Growth Factor (VEGF) Receptors (Flt-1 and Flk-1) Gene Suppressed the Growth of Murine Renal Cell Carcinoma
   Hiroshi Yazawa, Suzuki Yasuhiro, Lynnete Shorts, Eilene Grays, Robert H. Wiltrout, Morihiro Watanabe

Antibodies/Immunoconjugates

7. Anti-RLIP76 IgG Causes Apoptosis in Lung Cancer Cells and Synergistically Increases Anthracycline Cytotoxicity
   Sanjay Awasthi, Sharad S. Sighal

8. In-Vitro Evaluation of Anti-Ep-CAM Immunocytokine KS-IL2 in Ovarian Cancer
   Joseph P. Connor, Mildred Felder, Jackie Hank, Steve Gillies, Paul Sondel

9. Tumor Specific Antibodies from Breast Tumor Infiltrating B Cells
   Julia A. Coronella-Wood, Michelle Maly, Evan M. Hersh

10. The Pre-Clinincal Development of Two Novel Functional Monoclonal Antibodies Demonstrating Anti-Tumor Potential Against Breast Cancer
    Jean De Sousa-Hitzler, S. Hahn, V. Saldivia, F. McConkey, T. Groves, S.W. Fung, L. Martin, D.S. Young

11. Opsonization with Specific Antibodies Enhances Dendritic Cell Presentation of Apoptotic Tumor Cells and Induction of CTL
    Hubert Eng, Michelle Kuzma, Kate Agopsowicz, Christopher Zarozinski, Birgit C. Schultes

12. Therapeutic Application of an Anti-CD80 Antibody (IDEC-114) in B-Cell Lymphoma
    K. Hariharan, L.G. Berquist, T. Murphy, N. Hanna, G.R. Braslawsky, B.R. Leigh

13. Generation of a Human Anti-Heparanase Monoclonal Antibody for Anti-Cancer Therapy
    Steve Holmes, S. Mason, P. Brams

14. Clinical and Immunological Investigation of the Immunocytokine EMD 273063 (hu14.18-IL2) in Subjects with Metastatic or Recurrent Melanoma
    David King, Mark Albertini, Heidi Schalch, Jacquelyn Hank, Jean Surfus, Jacek Gan, Joan H. Schiller, David Mahvi, Kyungmann Kim, Ralph Reisfeld, Thomas Dahl, Oscar Kashala, Knut Sturmhoefel, Stephen Gillies, Paul Sondel

15. Pharmacokinetics and Pharmacodynamics of IDEC-152 Antibody in Chimpanzees after Multiple Subcutaneous Doses
    Be-Sheng Kuo, Ken R. Wey, Janet K. Clark, Ann Phan, John E. Leonard

16. A Chemokine Fusion Protein (LEC/chTNT-3) in Solid Tumor Immunotherapy
    Jiali Li, Peisheng Hu, Leslie A. Khawli, Alan L. Epstein

17. IDEC-152 (Anti-CD23) as a Potential Therapy for Chronic Lymphocytic Leukemia
    Nuzhat Pathan, Kandasamy Hariharan, Loic Scales, Peter Chu, Michael Hopkins, Alan Saven, Paul Grint, Bryan Leigh

18. A Newly Established Human Monoclonal Antibody, HMOCC-1 Recognizes Ovarian Cancer Cells
    Nao Suzuki, D. Aoki, K. Tsukazaki, N. Susumu, M. Sakayori, K. Orikawa, M. Mukai, I. Ishida, S. Nozawa

19. Various Immunostimulatory CpG Oligodeoxynucleotides Enhance the Anti-Tumor Activity Mediated by Antibodies by Activating Different Effector Cell Populations Including CD64 Expressing Cells
    Heidi van Ojik, Ch.E. Dahle, L. Bevaart, J. Bakker, M.J.H. Jansen, M.J. van Vugt, J.G.J. van de Winkel, G.J. Weiner

20. Phase I Trial of Bispecific Antibody MDX-H210 (FcãRI x HER-2/neu) Up to High Doses in Combination with G-CSF in Patients with Metastatic Breast Cancer
    Heidi van Ojik, R. Repp, Th. Valerius, G. Groenewegen, G. Wieland, Y. Deo, J.G.J. van de Winkel, J.R. Kalden, N. Lang, M. Gramatzki

Cytokines

21. Evidence for Paracrine Stimulation of Tumor Cell Survival during Pre-Angiogenic Phases of Growth
    Mark Dewhirst, Siqing Shan, Benjamin Moeller, Nicole Robson, Mariano Garcia-Blanco, Christopher Kontos

22. Interferon-a2b Exhibits Pleiotropic Immunomodulatory and Antitumor Effects in Metastatic Melanoma Leading to Apoptosis
    John Giannios, Emmanuel Michailakis

23. Altered Cytokine Production in Mice Lacking the Thymidine Phosphorylase Gene
    Misako Haraguchi, Hiroki Yoshida, Hiromitsu Hara, Shinjiro Hamano, Shin-ichi Akiyama

24. Differential Effect of IL-6 on Response to Oxidative Stress by Colorectal Carcinoma
    John Jessup, R. Samara, S. Lin

25. Induction of Complete Tumor Regression by IL-12 in a Novel Orthotopic Model of Murine Neuroblastoma: Potential Role of Tumor and/or Endothelia Cell Apoptosis
    Tahira Khan, Julie Hixon, Jim Stauffer, Erin Lincoln, Tim Back, Jon M. Wigginton

26. IL-12 Immunotherapy of Ovarian Cancer: Direct Upregulation of Fasl and Apoptosis Resistance in Human Ovarian Carcinoma Cell Lines
    Anna Lokshin, Eliezer Gorelik, Adele Marrangoni, Matthew Winans, Robert Edwards

27. NK Cells are a Source of Dendritic Cell-Mediated Immunoregulation: Two-Signal Requirement for NK Cells to Activate and Polarize DC
    Robbie Mailliard, Y. Son, R. Redlinger, A. Giermasz, P. Kalinsk

28. Induction of Anti-B16 Melanoma Responses in Mice by Albuleukin (TM), an Interleukin-2 (IL-2) / Human Serum Albumin Fusion Protein
    Robert Melder, Q. Wang, J. Lu, S. Bao

29. Nonviral Genetic Transfer of Fas Ligand in Combination with Cisplatin Induced Significant Growth Suppression in Prostate Cancer in Vivo
    Hiroyuki Nakanishi, Osam Mazda, Etsuko Satoh, Hiroyuki Morioka, Masahiro Nakao, Yoichi Mizutani, Jiro Imanishi, Tsuneharu Miki

30. Genomic and Proteomic Profiling of PBMC and Tumor Microenvironment Following Stimulation with High Doses IL-2
    Monica C. Panelli, Brian Martin, Dirk Nagorsen, Ena Wang, Kina Smith, Francesco M. Marincola

31. Activity of Inpatient Interleukin-2 in Patients with Melanoma or Kidney Cancer Unresponsive to Outpatient Interleukin-2
    Walter Quan, Jr., F.M. Quan

32. Outpatient Bolus Interleukin-2 in Kidney Cancer and Melanoma
    Walter Quan, Jr., F.M. Quan

33. Analysis of Serum Antibodies Present in Melanoma Patients Treated with Autologous Tumor Vaccine
    Patric Schiltz, S.H. Hendry, C.C. Malone, R.O. Dillman

34. Anti-Tumor Effects of Highly Efficient Systemic Interleukin-12 Gene Delivery in Murine Renal Cell Carcinoma
    Morihiro Watanabe, J. Ortaldo, T. Back J. Subleski, H. Yazawa, H. Suzuki, E. Parsoneault, V. Thillainathan, V. Vasquez, L.H. Shorts, R.H. Wiltrout

35. IL-12 cDNA Direct Injection into Tumor-Bearing or Non-Involved Spleen Results in a Similar Antimetastatic Effect
    Sharon Weber, Chen Qi, Zane Neal, Paul Sondel, David Mahvi

36. A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors
    Jon Wigginton, Maureen Edgerly, Peter Choyke, Robert Wiltrout, John Janik

37. Antitumoral Effects of Cationic Multilamellar Liposomes Containing Human Interferon-ƒÀ Gene against Human Renal Cell Carcinoma
    Kosuke Yamamoto, Hiroyuki Nakanishi, Yoichi Mizutani, Manabu Hatano, Masaaki Mizuno, Jun Yoshida, Tsuneharu Miki

38. Effect of Low-Dose Interleukin-2 Therapy on Clinical Toxicities and on Th2/Th1 Balance in Melanoma Patients Treated with Melanoma Peptide Vaccine
    Galina Yamshchikov, William Chad Cragun, Elisabeth M. H. Woodson, Kimberly A. Chianese-Bullock, Eric Bissonette, Catherine J. Wiernasz, Gina R. Petroni, Craig L. Slingluff, Jr.

Engineered T Cells

39. Autologous Peripheral Blood Lymphocytes and Cimetidine as Treatment of Metastatic Renal Cell Cancer, Colorectal Cancer, and Other Solid Tumors
    Robert O. Dillman, P.M. Schiltz, C. de Leon, C. DePriest, G. Soori, A.A. O’Connor, L.D. Beutel, S.K. Nayak

40. Ex Vivo Generation of Potent Cytotoxic T Lymphocytes for the Treatment of Cancer: A Novel Antigen Presentation System
    Didier J. Leturcq, J.M. Richards, M.R. Jackson, P.A. Peterson, A.M. Moriarty

41. Treatment of Advanced Malignant Melanoma with Ex Vivo-Generated Autologous T Cells with Specificity for Melanoma-Associated Target Antigens
    Jon M. Richards, M. Genge, L.A. Barbour, D.L. Leturcq, A.M. Moriarty, M.R. Jackson, P.A. Peterson

42. Single Activation Protocol Improves Vaccine-Primed T Cell Anti-Tumor Activity
    Jeffrey Sussman, R. Parihar, F.D. Finkelman

Immune Monitoring

43. Analytical Precision and Lot-to-Lot Variability of iTAg™MHC-Tetramer Detection of Antigen-Specific CD8+ Cells and Longitudinal Biological Variability of CMV Antigen-Specific Tetramer+ CD8+ Cells in Healthy Individuals
    Christopher Boyce, D.L. Broyles, J.S. Chamberlin, C.A. Johnson, N.T. Nguyen, S.L. Schubert, L.R. Lofaro, K.R. Bray

44. Characterization of CD8 Negative, HLA Class I/Epitope Tetrameric Complexes Binding T Cells
    Dirk Nagorsen, Vladia Monsurrò, Ena Wang, Francesco M. Marincola

45. Generation of iTAg™Tetramer-Binding, CD8 T Cells Using Antigen Presenting Cells Derived from PBMC under Different Culture Conditions
    Janice Payne, April Simora, Kristine Kuus-Reichel, Jennie Chang

46. Granzyme B ELISPOT Assay as an Alternative to the 51Cr-Release Assay for Immunological Monitoring
    Kimberly Shafer-Weaver, E.G. Derby, M.W. Baseler, A.M. Malyguine

New Therapies/Novel Agents

47. RNA Replicons Derived from Poliovirus are Directly Oncolytic in a Wide Array of Human Cancer Cells and Extend Survival of Mice Bearing Human Tumors
    David C. Ansardi, Donna C. Porter, Casey D. Morrow, Cheryl Jackson, G. Yancey Gillespie

48. Treatment of Cancer by Direct Intra-Tumor Injection of Granulocyte/Monocyte-Colony Stimulating Factor
    Stephen Brooks, H. Takita, K. Shin, S. Sharma, Y. Fang, C. Karakousis

49. Cytokines Mediated Regulation of Heat Shock Protein gp96
    Yuangen Chen, B.T. Ashok, V.P.S. Garikapaty, A. Mittelman, R.K. Tiwari

50. Antitumor Potential of IL-2 Activated Cord Blood
    Stanka Derzic, V. Slone, M. Schwartz, L. Sender

51. Cytotoxic T Lymphocyte Recognition of a Her-2/Neu-Derived Peptide Modified at HLA-A*0201 Anchor and Auxiliary Residues
    Sara Dionne, Douglas Lake

52. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2 (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex
    Clay Efferson, N.E. Ward, K. Kawano, A.P. Kudelka, C.A. O’Brian, C. G. Ioannides, J.L. Murray

53. Improved Therapy of Chemotherapeutic Drugs in Experimental Solid Tumors by Pretreatment with NHS76/PEP2, a Vascular Enhancing Agent
    Alan Epstein, L.A. Khawli, P. Hu

54. Oncogenes which Drive the Angiogenic Switch Provide a General Strategy for Discoverying Indirect Angiogenesis Inhibitors
    Judah Folkman

55. Eradication of Chemoresistant Aneuploid Metastatic Pancreatic Carcinoma Overexpressing CyclinD1, K-Ras and HER-2/Neu after Chemogene Treatment Consisting of Recombinant Replication Defective Adenovirus-p27 and Docetaxel
    John Giannios

56. Interferon-a2b & Doxycycline Activate Mitochondrial Pathway, DR-5 & Fas, Downregulate EGFR,MMP,bFGF & VEGF, Reduce S-100B,TA-90, AP, Ca, Hydroxy-Proline & Hyaluronidase Inducing Apoptosis in Stage IV Malignant Melanoma Metastasized to Proximal End of Femur
    John Giannios, Emmanuel Michailakis

57. An Antibody to DR5 (Trail-Receptor 2) Suppresses the Growth of Patient Derived Gastrointestinal Tumors Grown in Scid Mice
    Bonnie Hylander, R. Pitoniak, K. Sugamura, B. Gliniak, D. Lynch, D. Liebowitz, E.A. Repasky

58. MHC Class II Inducibility is Rescued in Noninducible LS1034 Colon Carcinoma Cell Line by Bryostatin I and Sodium Butyrate
    Yuri Kudinov, C.L. Wiseman, A.I. Kharazi

59. Increased Ability of Allogeneic NK Cells in the Purging of Leukemic Cells without Impairment of Reconstitution after Syngeneic Bone Marrow Transplantation
    William Murphy, Crystal Koh

60. Thermal Regulation of Dendritic Cell Activation and Migration
    Julie Ostberg, R. Patel, E. Kabingu, E.A. Repasky

61. Novel Recombinant Bispecific Molecules for Immunotherapy of B Cell Tumors
    Uwe Reusch, F. LeGall, B. Cochlovius, G. Moldenhauer, M. Little, S. Kipriyanov

62. Characterization of Surface Markers on Dendritic Cells Used to Support a Phase I/II Trial of Active Specific Immunotherapy for Metastatic Renal Cell Carcinoma Patients
    Patric Schiltz, K.S. Spencer, J.D. Novak, L.D. Beutel, R.O. Dillman

63. Immunomodulatory Effects of Combination Therapy with Histamine Dihydrochloride and Interleukin-2 During a Phase II Study in Stage IV Melanoma
    Theresa Whiteside, William Gooding, Elaine Elder, Laura Stover, John Glaspy, Kelly McMasters, Albert Deisseroth, Kristoffer Hellstrand, Peter Naredi, Kurt Gehlsen, Steven O’Day, Sanjiv Agarwala

64. Tumor Expression of 4-1BB Ligand: Sustenance for Tumor-lytic CD8+T Cells?
    Hua Zhang, Melinda S. Merchant, Kevin S. Chua, Elaine K. Thomas, Carl H. June, Crystal L. Mackall

Other

65. Helper-Dependent Adenovirus Produce Superior Transgene Expression in Human Dendritic Cells, but Still Stimulate Antiviral Immune Responses
    Sylvia Kiertscher, M.D. Roth, Q. Cheng, A. Harui, S.K. Basak, K. Mitani, T.A. Low

66. A Replication Competent Dual-Ad Vector for Treatment of Prostate Cancer
    Larisa Lillegren, Erica Podar, Lei Huang, Yanchun Lou, Steven Josephs, Elena Prokopenko, Brad Grimm, William McBride, Robert E. Sobol, Yawen L. Chiang, William C. Raschke

67. Comparison of 3 Different Methods for the Quantification of Circulating Tumor Cells in Blood of Patients with Epithelial Cancers
    Andreas Obwaller, Gottfried Himmler, Bernhard Peball, Philipp Oberkleiner, Hans Loibner, Thomas Bauernhofer, Hellmut Samonigg, Susanne Grunt

68. Alternatively Spliced Isoforms Yield Novel Epitopes for mAb Therapy
    Matthew Pando, M. Reff, H. Jordan, M. Brenner, G. Levinson, V. Kotraiah, F. Maurier, F. Coignard, B. Brinkman, K. McGowan, R. Einstein

69. Culture of T Cells from Pts with Renal Cell Carcinoma (RCC) with rhIL-2 Improves Redirected Cytotoxicity when Compared to Normal Donors
    Christopher Tretter, T. Crocenzi, M. Waugh, J. Fisher, B. Cole, D. Truman, N. Crosby, J. Heaney, M.S. Ernstoff

70. Interferon-Alpha Induced Depression: Research on Pathophysiological Mechanisms
    Arthur R. Van Gool, H.H. van Ojik, W.H.J. Kruit, M. Bannink, A.M.M. Eggermont, J.W. Gratama, T.L.M. Ten Hagen, M. Maes, R. van der Holt, M.W. Hengeveld, G. Stoter, D. Fekkes

Vaccines & Mechanisms

71. MAGE-1, a Cancer-Testis Antigen, Expression in Childhood Astrocytomas as an Indicator of Tumor Progression
    Bela Bodey, Stuart E. Siegel, Hans E. Kaiser

72. Rational Design of Completely Synthetic Liposomal Vaccines for Modulating Cellular and Humoral Immune Responses
    Vlad Budzynski, M. Krantz, R. Koganty

73. Recombinant Mycobacterial Vaccines for Cancer: Alternate Route of Ag-Processing to MHC Class-I in Dendritic Cells
    Eleanor J. Cheadle, Peter J. Selby, Andrew M. Jackson

74. Human Melanoma Cells May Proliferate after High-Dose Gamma-Irradiation: Guidelines for Safety Considerations in Preparing Autologous Tumor Cell Vaccines
    Donna Deacon, Erin Swanson, Kim Bullock, Craig L. Slingluff, Jr.

75. Early Results with a Vaccine of Cultured Autologous Tumor Cells and Dendritic Cells in Metastatic Melanoma and Renal Cell Cancer
    Robert O. Dillman, R.S. Selvan, P.M. Schiltz, C. de Leon, C. Peterson, K. Spencer, A. Beatty, C. DePriest, L.D. Beutel

76. Development of a Clinical Grade Production Process for a Melanoma Vaccine Based on Dendritic Cells Loaded with Allogeneic Tumor Cell Lysates as Antigen Source
    Marie-Therese Duffour, Paula Doceur, Isabelle Chauvet, Catherine Bardon-Defaye, Alessandra Nardin, Farad Heshmati, Jean-Pierre Abastado, Margarita Salcedo

77. Optimization of Antigen Load Schedule to Generate Mature DCs
    Nina Garlie, Eric Aoys

78. Active and Protective Immunity Induced by a Protein Based Vaccine Targeting the HER2/Neu Oncogenic
    Catherine Gerard, Mac Cheever, Nathalie Baudson, Terry Foy

79. Tumor-Derived Chaperone-Rich Cell Lysates Activate Dendritic Cells and Elicit Therapeutic Immunity against a Wide Variety of Cancers
    Michael Graner, Y. Zeng, H. Feng, E. Katsanis

80. Immunization of Melanoma Patients with Melan-A Peptide-Pulsed PBMC + rhIL-12 Induces Clinical Activity and Increased T Cell Responses: Lack of Correlation between T Cell Frequencies and Clinical Outcome
    Helena Harlin, Amy Peterson, Chris George, Thomas F. Gajewski

81. Characterization of Heteroclitic Analogs of Tumor-Associated CTL Epitopes Restricted by HLA-A3, -A24, and -B7
    Glenn Ishioka, X. Huang, A. Sette, J. Fikes

82. Rat and Human Glioma Cells Expressing the Membrane Form of Macrophage Colony Stimulating Factor (mM-CSF) are Killed in Animals via Paraptosis that is Associated with Increased Expression of 3 Different Heat Shock Proteins
    Martin Jadus, Y. Chen, M. Boldaji, C. Delgado, R. Sanchez, T. Douglass, U. Al-Atar, W. Schulz, E.W.B. Jeffes

83. Induction of Specific Anti-Tumor Immunity with an Electrofusion Product between Tumor Cells and Dendritic Cells
    Johanne Kaplan, K.L. Vergilis, J. Shields, C. Johnson, M. Vasconcelles, W.M. Siders

84. Induction of Myeloid Leukemia-Derived Antigen Presenting Cells by Retinoic Acid and CD40-Ligand
    Kazunori Kato, Satoshi Takahashi, Hirofumi Hamada

85. Low Thymic Output and/or Rapid Lymphocyte Turnover in the Circulation of Patients with Head and Neck Cancer
    Iris Kuss, Tony E. Godfrey, Albert D. Donnenberg, Robert L. Ferris, Jeffrey M. Harris, Joseph M. McCune, William Gooding, Theresa L. Whiteside

86. Vaccination with Alum-Adsorbed Antibodies against EpCAM Directly Induces Anti-EpCAM Antibodies
    Hans Loibner, Manfred Schuster, Gottfried Himmler

87. AdCD40L Immunogene Therapy Counteracts IL10 Induced Anergy
    Angelica Loskog, Helena Dzojic, Sofia Vikman, Thomas Totterman

88. Potential Epitopes for Anti-Idiotype Vaccination for T-ALL: Childhood T-ALL Exhibit Complex T-Cell Receptor Gene Rearrangements
    David Margolis, James Casper, Teresa Janczak, Laura McOlash, Bryon Johnson

89. HIV Immunogens Delivered in an Adenoviral Vaccine Vector Elicit Strong Cellular Immune Responses
    Girija Muralidhar, Manjula Navaratnam, Larisa Lillegren, Mangala Hariharan, Yawen L. Chiang, Robert E. Sobol, Sybille L. Sauter

90. Antigen Presentation by Mature or Immature Dendritic Cells Infected with Recombinant Vaccinia-Virus
    Dirk Nagorsen, Monica Panelli, Mark E. Dudley, Steven A. Rosenberg, Francesco M. Marincola

91. Hu14.18-IL2 Immunocytokine Plus Systemic IL-2 Combinatorial Therapy: Prevention of Tumor Escape
    Zane Neal, Alexander Rakhmilevich, Jacquelyn Hank, Holger Lode, Ralph Reisfeld, Stephen Gillies, Paul Sondel

92. A Validated Computer Model of the Cell-Mediated Responses to Vaccine Therapy of Three Tumors Systems in the C57B/6 Mouse
    Ami Radunskaya, Lisette dePillis, Charles Wiseman

93. Vaccine-Induced CD8+ T Cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma
    Sandra Reynolds, A.Z. Jacquotte, R.L. Shapiro, D.F. Roses, M.N. Harris, D. Johnston, J.C. Bystryn

94. Identification and Immunotherapy of T-Cell Defined Tumor-Specific Epitopes in Recoverin, SYT-SSX Chromosomal Translocation Protein and a New Transcription Protein
    Noriyuki Sato, T. Torigoe, S. Kawaguchi, T. Tsukahara, Y. Nabeta, K. Ida, Y. Sato, A. Maeda, H. Ohguro, T. Yamashita, H. Ikeda

95. Generation of Cultured Autologous Tumor Cells for Tumor Cell-Pulsed Dendritic Cell Vaccines in Human Metastatic Melanoma and Renal Cell Cancer
    Rathinam Selvan, A. Beatty, J. Novak, K. Spencer, B.W. Brown and R.O. Dillman

96. Establishment of Human Renal Cell Carcinoma Cell Lines for Generating Autologous Tumor Cell Vaccine: Overcoming Major Limiting Factor of Outgrowth of Normal Epithelial Cells in Tumor Tissue Culture
    Rathinam Selvan, B.W. Brown, S. Ravi, F.S. Heinemann, N. Rao, R.O. Dillman

97. Clinical and Immunological Evaluation of Hormone-Refractory Prostate Cancer Patients Treated with DCVax™Prostate in a Phase I/II Trial
    Gopi Shankar, Heather Kelley, Linda Samadzadeh, Anne Lodge, Alton Boynton, Christos Papandreou, Christopher Logothetis, Arie Belldegrun, Abdel Aziz Elgamal

98. Functional Reactivity of Circulating T-Cells which Recognize Melanoma-Associated Antigens from Normal Donors and Peptide-Immunized Patients
    Manish Sharma, Peter P. Lee, James J. Mule’, Jeffrey S. Weber

99. CpG 7909 a Promising Adjuvant to Vaccination with MAGE-3 Protein in Patients with MAGE-3 Positive Tumors Results of a Phase I/II Study
    Heidi H. van Ojik, W.H.J. Kruit, J. P. Portielje, V. Brichard, R. Verloes, M. Delire, G. Stoter

100. Development of Tumor-Specific Immunotherapy Targeting IAP Family Proteins
     Toshihiko Torigoe, S. Idenoue, Y. Hirohashi, M. Yamamoto, H. Hariu, H. Asanuma, A. Yagihashi, H. Ikeda, N. Sato

101. Generation of Dendritic Cell-Tumor Cell Hybrids for Clinical Vaccine Application
     Katrina Trevor, Emmanuel Akporiaye, Evan Hersh, Cathleen Cover, Didier Landais, Rachel Taylor, Alan King, Richard Walters

102. Enhancement of Cytotoxic T Lymphocyte Responses in Patients with Gastrointestinal Malignancies Following Vaccination with CEA Peptide Pulsed Dendritic Cells
     Takuya Tsunoda, Kenji Matsuda, Hiroki Yamaue

103. Whole-Cell Tumor Vaccine for Human Renal Carcinoma: Preliminary Results in 14 Cases
     Charles Wiseman, A. Kharazi, Y. Kudinov

104. The Human Papillomavirus 16 E6 Variant L83V Linked to Human Leukocyte Antigen B*51 is Associated with Higher Frequency of Cervical Cancer
     Ingeborg Zehbe, Joannis Mytilineos, Ingrid Wikstrom, Rudi Hendriksen, Karin Stalberg, Massimo Tommasino

105. Exogenous Stress Proteins Enhance the Immunogenicity of Apoptotic Tumor Cells and Stimulate Anti-Tumor Immunity
     Yi Zeng, H. H. Feng, M.W. Graner, A. Likhacheva, E. Katsanis